Takeda Pharmaceutical Co. Ltd.’ efforts over the last five years to reshape its pipeline – including the merger with Shire PLC – are now poised to deliver. The Japanese pharma held its first ever investor day in New York on 14 November, coming after the company's stock was listed on the New York Stock Exchange in 2018 and the merger with Shire was completed in January.
With the integration of Shire largely completed, Takeda CEO Cristophe Weber, R&D president Andy Plump and other R&D leaders set...








